Latest Safety News

Austco Healthcare has landed a $2.1 million deal to supply its Tacera nurse call system for a major new patient and surgical tower at Toronto Western Hospital, marking a significant step in its North American expansion.

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Life360, Inc. reported a strong Q1 2025 with 32% revenue growth to $103.6 million, driven by a 33% increase in subscription revenue and a return to profitability with $4.4 million net income. The company also advanced its strategic positioning through a $4.5 million acquisition and a key partnership.

Life360’s Q1 2025 results reveal robust revenue growth, expanding profitability, and a bullish outlook for FY 2025, driven by a scalable freemium model and international expansion.

Life360 has reported a landmark first quarter in 2025, with soaring user engagement and robust revenue growth that underscore its resilience in a cautious consumer market.

Envirosuite Limited has entered a binding Scheme Implementation Deed with UK-based Ideagen Limited, agreeing to a full acquisition at a significant premium. The transaction values Envirosuite at approximately A$132.2 million and awaits shareholder and regulatory approvals.

Noronex Limited has appointed seasoned mining executive Victor Rajasooriar as Managing Director and CEO to spearhead growth in its Kalahari Copper Belt portfolio. This leadership change comes alongside a strategic share subscription and the retirement of a founding director.

Emperor Energy's Environmental Plan for the Judith-2 Well has passed NOPSEMA's completeness check and is now open for public comment, marking a key regulatory milestone on the path to drilling in mid-2026.

South32 has announced a planned CEO transition with Matthew Daley joining as Deputy CEO in February 2026 and succeeding Graham Kerr later that year, marking a new chapter for the mining giant.

Radiopharm Theranostics has secured Data Safety and Monitoring Committee approval to escalate dosing in its Phase 1 trial of 177Lu-RAD204, expanding patient cohorts across multiple cancer types.

Dyno Nobel Limited reported a $25 million EBIT uplift in its 2025 half-year results, driven by its ongoing transformation program and strategic moves to separate its Fertilisers business. Despite weather-related challenges, the company is progressing key asset sales and preparing for a share buyback resumption.

Dyno Nobel Limited reports a statutory net profit of $7 million for 1H25, reversing a prior loss, as it advances key sales agreements to separate its Fertilisers business and accelerates its transformation program.